June 15, 2018 07:26 AM EDTUpdated 11:19 AM

Verrica Pharma bankrolls PhIII with a $75M IPO raise for lead skin drug

Amber Tong

Just in case you’re wondering if the biotech IPO window is still open, dermatology biotech Verrica Pharmaceuticals has bagged $75 million in its Nasdaq …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Verrica Pharma bankrolls PhIII with a $75M IPO raise for lead skin drug

Amber Tong

Sign up to read this article for free.

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Ver­ri­ca Phar­ma bankrolls PhI­II with a $75M IPO raise for lead skin drug

Amber Tong

Sign up to read this article for free.

more like this

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Verrica Pharma bankrolls PhIII with a $75M IPO raise for lead skin drug

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings